Biofrontera Announces Ameluz® Clinical Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy BFRI?
Source: Newsfilter
- Clinical Trial Results: Biofrontera's Phase 2b study demonstrated that Ameluz® achieved a 57.97% reduction in inflammatory acne lesions with a 3-hour incubation, significantly outperforming the control group's 36.51%, indicating the treatment's potential in acne management.
- Efficacy Assessment: In the mIGA analysis, 25% of patients treated with Ameluz® met the co-primary endpoint compared to 21.4% in the vehicle group, further validating Ameluz®'s effectiveness in improving skin conditions.
- Safety and Tolerability: Ameluz® exhibited a favorable safety profile, with treatment-related adverse events primarily consisting of mild to moderate burning sensations and pruritus, and average pain scores during the 3-hour treatments ranged from 3.4 to 3.8, indicating good tolerability.
- Market Potential: Acne vulgaris is one of the most common dermatological conditions in the U.S., and Biofrontera plans to present these findings to the FDA in Q3 2026 to seek approval for Ameluz® in treating moderate to severe acne, thereby expanding its dermatology product line.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BFRI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BFRI
Wall Street analysts forecast BFRI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.824
Low
3.00
Averages
6.00
High
9.00
Current: 0.824
Low
3.00
Averages
6.00
High
9.00
About BFRI
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biofrontera to Report 2025 Financial Results on March 19
- Financial Reporting Schedule: Biofrontera will announce its financial results for the year ended December 31, 2025, after the U.S. market closes on March 19, 2026, reflecting the company's commitment to financial transparency.
- Conference Call Timing: The company will host a conference call at 10:00 AM ET on the same day to discuss the financial results and provide a business update, aiming to bolster investor confidence in the company's future prospects.
- Product Focus Area: Biofrontera specializes in photodynamic therapy (PDT), commercializing the drug-device combination Ameluz® with the RhodoLED® lamp series for treating precancerous skin lesions, showcasing its expertise in dermatological treatments.
- Clinical Trial Expansion: The company is conducting clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate-to-severe acne, indicating its proactive approach to product development and market expansion potential.
See More
Biofrontera Announces Ameluz® Clinical Trial Results
- Clinical Trial Results: Biofrontera's Phase 2b study demonstrated that Ameluz® achieved a 57.97% reduction in inflammatory acne lesions with a 3-hour incubation, significantly outperforming the control group's 36.51%, indicating the treatment's potential in acne management.
- Efficacy Assessment: In the mIGA analysis, 25% of patients treated with Ameluz® met the co-primary endpoint compared to 21.4% in the vehicle group, further validating Ameluz®'s effectiveness in improving skin conditions.
- Safety and Tolerability: Ameluz® exhibited a favorable safety profile, with treatment-related adverse events primarily consisting of mild to moderate burning sensations and pruritus, and average pain scores during the 3-hour treatments ranged from 3.4 to 3.8, indicating good tolerability.
- Market Potential: Acne vulgaris is one of the most common dermatological conditions in the U.S., and Biofrontera plans to present these findings to the FDA in Q3 2026 to seek approval for Ameluz® in treating moderate to severe acne, thereby expanding its dermatology product line.
See More
BIOFRONTERA INC PLANS TO SUBMIT PHASE 2B DATA FOR AMELUZ PDT TO FDA IN Q3 2026
Project Overview: The BioFrontier AI initiative is set to present Phase 2 data for the Ameluz PDT treatment in Q3 2026.
Focus on Ameluz: The data presentation will specifically highlight the efficacy and outcomes of Ameluz in photodynamic therapy (PDT).
See More
BIOFRONTERA INC - AMELUZ PDT SHOWS POSITIVE SAFETY RESULTS IN PHASE 2B TRIAL
Study Overview: A Phase 2 study by BioFrontier AI demonstrates a favorable safety profile for a new treatment.
Implications for Treatment: The findings suggest potential advancements in therapeutic options based on the study's results.
See More
BIOFRONTERA INC - PHASE 2B STUDY DEMONSTRATES SIGNIFICANTLY LOWER INFLAMMATORY ACNE LESIONS WITH AMELUZ PDT
Study Overview: A Phase 2 study has been conducted to evaluate the effects of a treatment on inflammatory acne lesions.
Results: The study shows a significant reduction in inflammatory acne lesions with the use of the treatment, Ameluz PDT.
See More
BIOFRONTERA INC. ANNOUNCES ENCOURAGING PHASE 2B RESULTS FOR CONTINUED DEVELOPMENT OF AMELUZ® PHOTODYNAMIC THERAPY IN TREATING MODERATE TO SEVERE ACNE VULGARIS
Positive Phase 2 Results: BioFrontier AI has reported positive results from Phase 2 trials supporting the development of its AmeLuz® photodynamic therapy.
Targeted Condition: The therapy is aimed at treating moderate to severe acne vulgaris, indicating a potential advancement in acne treatment options.
See More
Biofrontera to Report 2025 Financial Results on March 19
- Financial Reporting Schedule: Biofrontera will announce its financial results for the year ended December 31, 2025, after the U.S. market closes on March 19, 2026, reflecting the company's commitment to financial transparency.
- Conference Call Timing: The company will host a conference call at 10:00 AM ET on the same day to discuss the financial results and provide a business update, aiming to bolster investor confidence in the company's future prospects.
- Product Focus Area: Biofrontera specializes in photodynamic therapy (PDT), commercializing the drug-device combination Ameluz® with the RhodoLED® lamp series for treating precancerous skin lesions, showcasing its expertise in dermatological treatments.
- Clinical Trial Expansion: The company is conducting clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate-to-severe acne, indicating its proactive approach to product development and market expansion potential.
See More
Biofrontera Announces Ameluz® Clinical Trial Results
- Clinical Trial Results: Biofrontera's Phase 2b study demonstrated that Ameluz® achieved a 57.97% reduction in inflammatory acne lesions with a 3-hour incubation, significantly outperforming the control group's 36.51%, indicating the treatment's potential in acne management.
- Efficacy Assessment: In the mIGA analysis, 25% of patients treated with Ameluz® met the co-primary endpoint compared to 21.4% in the vehicle group, further validating Ameluz®'s effectiveness in improving skin conditions.
- Safety and Tolerability: Ameluz® exhibited a favorable safety profile, with treatment-related adverse events primarily consisting of mild to moderate burning sensations and pruritus, and average pain scores during the 3-hour treatments ranged from 3.4 to 3.8, indicating good tolerability.
- Market Potential: Acne vulgaris is one of the most common dermatological conditions in the U.S., and Biofrontera plans to present these findings to the FDA in Q3 2026 to seek approval for Ameluz® in treating moderate to severe acne, thereby expanding its dermatology product line.
See More
BIOFRONTERA INC PLANS TO SUBMIT PHASE 2B DATA FOR AMELUZ PDT TO FDA IN Q3 2026
Project Overview: The BioFrontier AI initiative is set to present Phase 2 data for the Ameluz PDT treatment in Q3 2026.
Focus on Ameluz: The data presentation will specifically highlight the efficacy and outcomes of Ameluz in photodynamic therapy (PDT).
See More
BIOFRONTERA INC - AMELUZ PDT SHOWS POSITIVE SAFETY RESULTS IN PHASE 2B TRIAL
Study Overview: A Phase 2 study by BioFrontier AI demonstrates a favorable safety profile for a new treatment.
Implications for Treatment: The findings suggest potential advancements in therapeutic options based on the study's results.
See More
BIOFRONTERA INC - PHASE 2B STUDY DEMONSTRATES SIGNIFICANTLY LOWER INFLAMMATORY ACNE LESIONS WITH AMELUZ PDT
Study Overview: A Phase 2 study has been conducted to evaluate the effects of a treatment on inflammatory acne lesions.
Results: The study shows a significant reduction in inflammatory acne lesions with the use of the treatment, Ameluz PDT.
See More
BIOFRONTERA INC. ANNOUNCES ENCOURAGING PHASE 2B RESULTS FOR CONTINUED DEVELOPMENT OF AMELUZ® PHOTODYNAMIC THERAPY IN TREATING MODERATE TO SEVERE ACNE VULGARIS
Positive Phase 2 Results: BioFrontier AI has reported positive results from Phase 2 trials supporting the development of its AmeLuz® photodynamic therapy.
Targeted Condition: The therapy is aimed at treating moderate to severe acne vulgaris, indicating a potential advancement in acne treatment options.
See More
